• Most Popular
  • Most Shared

India's Lupin says to sell lisinopril tablets in UK

Mon Jul 2, 2007 1:27am EDT

Stocks

   

MUMBAI, July 2 (Reuters) - Indian drug maker Lupin Ltd. (LUPN.BO) has received approval from British authorities to sell lisinopril tablets, a cardiac drug, the company said on Monday.

The drug is the generic equivalent of Merck and Co.'s (MRK.N) Prinivil tablets, which have UK sales of about $46 million, Lupin said in a statement.

"This approval is the first of a series of approvals that we expect in UK and Europe in the next few months," Managing Director Kamal Sharma said. Lupin's shares were 0.2 down 0.2 percent at 731 rupees in a firm Mumbai market at 0520 GMT.

((Reporting by Himangshu Watts; Reuters Messaging: himangshu.watts.reuters.com@reuters.net +91 22 6636 9030)) Keywords: LUPIN APPROVAL/

(C) Reuters 2007. All rights reserved. Republication or redistribution ofReuters content, including by caching, framing or similar means, is expresslyprohibited without the prior written consent of Reuters. Reuters and the Reuterssphere logo are registered trademarks and trademarks of the Reuters group ofcompanies around the world.nBOM239587


More from Reuters

Photo

White House backs healthcare deal, sees victory

WASHINGTON (Reuters) - The White House on Sunday sought to preserve the fragile alliance of Democratic liberals and moderates backing broad healthcare reform legislation, with tough decisions looming on abortion and a new government-run insurance program. | Video

» More Top News
A woman shops at a Sam's Club store, a division of Wal-Mart Stores, in Bentonville, Arkansas June 4, 2009. REUTERS/Jessica Rinaldi

The food-stamp economy

On the last day of every month, shoppers at Walmart load their carts with food and household items and wait for the midnight hour. Is this the new normal in America?  Full Article 

U.S.
Two men shake hands in a file photo. REUTERS/File

Let's make a deal

The battered M&A sector will make a tepid recovery in the coming year and three hot sectors will lead the way, according to a Thomson Reuters analysis.  Full Article 

Global Deals Review